Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome

Overview of attention for article published in Frontiers in immunology, September 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

policy: 1 policy source

twitter: 3 X users

Readers on

mendeley: 34 Mendeley

Summary Policy documents X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 35,552 followers.

Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome. https://t.co/fHadJ4uTUP https://t.co/wIFKRzfzLs

16 Oct 2018

Reply Repost Favourite

RT @FrontImmunol: Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome: Julie Barsalou, Annaliesse Blinco…

25 Sep 2018

Reply Repost Favourite

Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome: Julie Barsalou, Annaliesse Blincoe, Isabel Fernandez, Dorothée Dal-Soglio, Lorie Marchitto, Silvia Selleri, Elie Haddad, Aissa Benyoucef, Fabien Touzot https://t.co/wgj

25 Sep 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.